Nurse Practitioner in Fife, WA Accepting Medicare
4 Nurse Practitioner nurses found. Showing 1 - 4
 Miss Loan Vu Minh Pham, DNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 4505 Pacific Hwy E Ste C2, Fife, WA 98424 Phone: 714-880-5065 |
Ida Louise Campbell, FNP Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 502 54th Ave E, Fife, WA 98424 Phone: 253-459-7500 Fax: 253-459-7527 |
Dr. Adrianne Papoff-wallace, ARNP Nurse Practitioner - Psych/Mental Health Medicare: Medicare Enrolled Practice Location: 3203 Wilton Ln E, Fife, WA 98424 Phone: 253-533-5768 Fax: 866-638-7530 |
Jane Nyaguthii Tellis, PMHNP Nurse Practitioner - Psych/Mental Health Medicare: Accepting Medicare Assignments Practice Location: 2150 Freeman Rd E, Fife, WA 98424 Phone: 263-942-5644 |
News Archive
Femtogenix announces new data on ADCs containing reduced potency payloads in solid tumor models
Femtogenix Ltd, a UK biotechnology company developing the next generation of DNA-interactive Antibody Drug Conjugate payloads, today announced data demonstrating the potent efficacy and favorable toxicity profile of a reduced potency analogue from its Pyridinobenzodiazepine ADC payload platform in solid tumor models.
PET imaging can enable accurate diagnosis of recurring brain metastases
For patients with brain metastases, amino acid positron emission tomography (PET) can provide valuable information about the effectiveness of state-of-the-art treatments.
Temporary blood pressure drops in middle age may increase risk of dementia in later years
Middle-aged people who experience temporary blood pressure drops that often cause dizziness upon standing up may be at an increased risk of developing cognitive decline and dementia 20 years later, new Johns Hopkins Bloomberg School of Public Health research suggests.
FDA advisory committee votes against Avodart sNDA for prostate cancer risk reduction
GlaxoSmithKline today announced the results of a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting to discuss the supplemental New Drug Application (sNDA) for Avodart® (dutasteride) for reducing the risk of prostate cancer in men at risk for the disease, defined as those who have had a prior negative biopsy due to clinical concern and have an elevated serum prostate-specific antigen (PSA).
› Verified 2 days ago